Abstract
Researchers at the University of Central Florida and
Southern Methodist University have developed novel carbapenem antibiotics that
exhibit enhanced activity against drug-resistant strains of mycobacterial
species, such as Mycobacterium tuberculosis (Mtb) and Micobacterium abscessus
(Mabs). The narrow-spectrum carbapenems selectively target mycobacterial L, D-transpeptidases.
In contrast to broad spectrum carbapenem antibiotics, treatment with these carbapenems
may have less adverse effects on the microbiome. A structural modification at the
C5 position endows the new carbapenems with improved potency and selectivity.
Benefit
Provides improved activity against both Mtb and Mabs compared to the antibiotic meropenem in vitroPotentially minimizes adverse effects on the microbiome, compared to broad-spectrum antibioticsMarket Application
Narrow spectrum antibiotics for treating drug-resistant strains of mycobacterial species
Brochure
